Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer

The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report. In a Sept. 26 research note, Dawson James Securities analyst Jason Kolbert reported that IsoRay Inc. (ISR:NYSE.MKT) launched a new marketing campaign call...
Streetwise Reports | October 1, 2019 |

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. In a March 18 research note, H.C. Wainwright & Co. analyst Andrew Fein purported that Constellation Pharmaceuticals Inc.'s (CNST:NASDAQ) "strong and balanced pi...
Streetwise Reports | March 25, 2019 |

Truly Epic Silver Signals: Vying for Your Attention

If we had to pick one day, or one situation when a single market provided most indications during a single day, it would be yesterday’s performance of silver. There’s not much to say about yesterday’s session while looking at...
Przemyslaw Radomski, CFA | July 17, 2019 |

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types

This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. In a Feb. 20 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that CytoDyn Inc. (CYDY:OTCQB) plans to...
Streetwise Reports | March 1, 2019 |

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. ...
Streetwise Reports | November 18, 2019 |

The Last Hawk Flew to Heaven

Sad moment. Paul Volcker, the former Fed Chairman went to Bank of Heaven. We are not reporting this news due to the implications for gold prices, but as an opportunity to reflect on changes in the central banking since the time of Tall Paul and on their consequences for the go...
Arkadiusz Sieron | December 11, 2019 |

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. In a Dec. 12 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) plans to ...
Streetwise Reports | December 19, 2019 |

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'

The key business and investment points are presented in a ROTH Capital Partners report. In a Dec. 18 research note, analyst Jonathan Aschoff reported that ROTH Capital Partners initiated coverage on Inovio Pharmaceuticals Inc. (INO:NASDAQ) with a Buy rating and a "c...
Streetwise Reports | December 27, 2019 |
1 2 3